ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
US Tech 100
17,446.00
2.17%
Dow Jones
38,675.68
1.18%
Brent Oil
82.765
0.00%
Bitcoin
63,829.69
1.50%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. 23andMe Holding Company (ME) Quote

23andMe Holding Company

23andMe Holding Company (ME)

Moneta Gold Inc
0.5023
-0.0023
(-0.46%)
Closed May 04 4:00PM
Delayed by 15 minutes
0.509
0.0067
(1.33%)
After Hours: 7:59PM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
0.509
Bid
0.495
Ask
0.509
Volume
2,216,423
0.49 Day's Range 0.5151
0.35 52 Week Range 2.21
Market Cap
241.458M
Previous Close
0.5046
Open
0.5022
Last Trade
200
@
0.509
(formt)
Last Trade Time
Financial Volume
$ 1,119,322
VWAP
0.505013
Average Volume (3m)
7,227,841
Shares Outstanding
482,916,636
Dividend Yield
-
PE Ratio
-0.77
Earnings Per Share (EPS)
-0.65
Revenue
299.49M
Net Profit
-311.66M

About 23andMe Holding Company

23andMe is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic t... 23andMe is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. More than 80% of 23andMe customers voluntarily elect to share their de-identified genetic data with the company, which is used to develop future reports. In 2018, GlaxoSmithKline made an equity investment in the company, entering a five-year collaborative agreement with 23andMe to develop drug candidates. Show more

Sector
Pharmaceutical Preparations
Industry
Blank Checks
Website
www.23andme.com
Headquarters
Wilmington, Delaware, USA
Founded
2021
23andMe Holding Company is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ME. The last closing price for 23andMe was $0.50. Over the last year, 23andMe shares have traded in a share price range of $ 0.35 to $ 2.21.

23andMe currently has 482,916,636 shares outstanding. The market capitalization of 23andMe is $241.46 million. 23andMe has a price to earnings ratio (PE ratio) of -0.77.

ME Latest News

More News

Potter Handy Law Firm Represents Nearly 5,000 Clients in 23andMe Data Breach Case

Potter Handy LLP, a leading consumer privacy law firm, today announced that it is representing nearly 5,000 individuals in California and Illinois impacted by the massive data breach at genetic...

April 30 2024
Business Wire

23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced that two...

April 24 2024
GlobeNewswire Inc.

23andMe announces CEO’s intention to pursue a potential take-private

SOUTH SAN FRANCISCO, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, has been made aware that Anne Wojcicki...

April 18 2024
GlobeNewswire Inc.

23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024

23ME-01473, antibody targeting ULBP6: Data will be presented on the discovery and biology of ULBP6, and the potential to restore natural killer and T cell-mediated anti-tumor immunity by targeting...

April 05 2024
GlobeNewswire Inc.

23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6

23ME-01473 (‘1473) seeks to restore anti-tumor immunity through NK and T cells by blocking the immunosuppressive effects of soluble ULBP6 ‘1473 also induces Fc receptor-mediated killing of...

March 20 2024
GlobeNewswire Inc.

23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago

SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, released an exciting new feature for...

March 19 2024
GlobeNewswire Inc.

23andMe Launches New Genetic Reports on Common Forms of Cancer

SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, released three new genetic reports for...

March 06 2024
GlobeNewswire Inc.

23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024

SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced an oral...

March 05 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

February 21 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

February 07 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.05411.86813186810.4550.52880.450232460010.50019126CS
40.0347.157894736840.4750.6190.3571502250.4800214CS
12-0.141-21.69230769230.650.8260.3572278410.54900562CS
26-0.371-42.15909090910.881.020.3562621200.66891114CS
52-1.411-73.48958333331.922.210.3544771780.90031009CS
156-10.491-95.37272727271113.680.3534542523.00316449CS
260-10.491-95.37272727271113.680.3534542523.00316449CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BENFBeneficient
$ 6.8001
(254.17%)
31.01M
SGBXSafe and Green Holdings Corporation
$ 5.49
(87.37%)
92.18M
SHOTWSafety Shot Inc
$ 0.45
(45.16%)
644
AIPArteris Inc
$ 8.185
(38.03%)
1.11M
RGFReal Good Food Company Inc
$ 0.85
(37.32%)
4.26M
MNDRMobile health Network Solutions
$ 3.33
(-84.91%)
18.76M
NUVOHoldco Nuvo Group DG Ltd
$ 2.00
(-57.54%)
1.04M
SPTSprout Social Inc
$ 28.82
(-40.15%)
13.47M
UNITUniti Group Inc
$ 4.441
(-26.35%)
21.07M
IPDNProfessional Diversity Network Inc
$ 1.29
(-24.12%)
662.59k
AAPLApple Inc
$ 183.38
(5.98%)
163.22M
SQQQProShares UltraPro Short QQQ
$ 11.08
(-5.94%)
154.59M
JAGXJaguar Health Inc
$ 0.3164
(7.91%)
142.47M
NKLANikola Corporation
$ 0.6526
(6.55%)
106.88M
SGBXSafe and Green Holdings Corporation
$ 5.49
(87.37%)
92.18M

ME Discussion

View Posts
Afterhoursearnings3 Afterhoursearnings3 2 weeks ago
Not great, but that's part of the game friend. Sometimes you lose.
👍️0
Pisd Pisd 2 weeks ago
..only $170M market cap, sell to highest bidder! ME$$,,,
👍️0
Pisd Pisd 2 weeks ago
AI, law enforcement/gov, pharma want ME dna database imo...
👍️0
ErnieBilco ErnieBilco 2 weeks ago
Corporate theft IMO. The CEO and her board of minions should be excluded from any voting on this.
👍️0
Pisd Pisd 2 weeks ago
Let insiders take private?, voting NO here...
👍️0
PapaSizz PapaSizz 3 weeks ago
How'd that work out?
👍️0
Monksdream Monksdream 1 month ago
It doesn’t bother me, since I have lots of money to buy shares of a company like Curtis-Wright
👍️0
ErnieBilco ErnieBilco 1 month ago
Kathy Hibbs is selling about 35K shares per week but it should slow down since the price is now lower than what she gets them for. 42 cents

She only has like 115K left before they reload to feed themselves more shares
👍️0
Monksdream Monksdream 1 month ago
ME new 52 lo
👍️0
ErnieBilco ErnieBilco 2 months ago
Didn't like it in the .60 and see even less to like at .44 -

I have only one question - Will it be a quick BK or a slow drawn out worthless attempt to infuse some sort of actual value?
👍️0
Monksdream Monksdream 2 months ago
ME new 52 week low
👍️0
ErnieBilco ErnieBilco 3 months ago
Hey I'm a gambler but I'm not willing to put any money into this. The Q reads like a failing business venture to me. I saw absolutely no bright spots in the filing. It was worth a look to save my funds from devastating losses.
👍️0
Afterhoursearnings3 Afterhoursearnings3 4 months ago
Grabbed a butt load at .8
👍️0
mick mick 4 months ago
https://www.otcmarkets.com/stock/ME
👍️0
mick mick 5 months ago
https://www.otcmarkets.com/stock/ME
👍️0
mick mick 6 months ago
https://www.otcmarkets.com/stock/ME
👍️0
Afterhoursearnings3 Afterhoursearnings3 7 months ago
Buyside bias last 5 sessions. Will pop
👍️0
Monksdream Monksdream 7 months ago
ME new 52 week low
👍️0
Monksdream Monksdream 7 months ago
ME new 52 week low
👍️0
mick mick 7 months ago
https://www.otcmarkets.com/stock/ME
👍️0
Monksdream Monksdream 7 months ago
ME new 52 week low
👍️0
Monksdream Monksdream 7 months ago
ME new 52 week low
👍️0
Awl416 Awl416 8 months ago
23andMe Granted New FDA Clearance to Report Additional BRCA Variants
👍️0
Afterhoursearnings3 Afterhoursearnings3 8 months ago
Hammer bottom
👍️0
Monksdream Monksdream 9 months ago
ME new 52 Week low
👍️0
Monksdream Monksdream 9 months ago
ME new 52 week low
👍️0
mick mick 9 months ago
ME
23andMe Holding Company
1.51
-0.015 (-0.98%)
Volume: 2,773,867
Day Range: 1.45 - 1.53
Last Trade Time: 7:59:42 PM EDT
👍️0
Monksdream Monksdream 9 months ago
ME new 52 week low
👍️0
Monksdream Monksdream 9 months ago
23andMe Holding Co. NASDAQ: ME

GoSymbol lookup
Health Care : Health Care Providers & Services | Small Cap BlendCompany profile
23andMe Holding Co. is a genetics-led consumer healthcare and therapeutics company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients’ lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.
👍️0
propert propert 9 months ago
Great news today, anyone else excited by that green hammer at the close? Let's rock on Monday!
👍️0
mick mick 10 months ago
ME
23andMe Holding Company
1.67
0.04 (2.45%)
Volume: 1,009,450
Day Range: 1.64 - 1.71
Last Trade Time: 7:59:13 PM EDT
👍️0
mick mick 10 months ago
ME
23andMe Holding Company
1.64
0.05 (3.14%)
Volume: 7,698,993
Day Range: 1.57 - 1.65
Last Trade Time: 7:58:30 PM EDT
👍️0
mick mick 11 months ago
ME
23andMe Holding Company
2.07
0.03 (1.47%)
Volume: 4,213,342
Day Range: 1.8338 - 2.10
Last Trade Time: 7:59:16 PM EDT
👍️0
mick mick 1 year ago
ME
23andMe Holding Company
1.99
0.11 (5.85%)
Volume: 1,349,148
Day Range: 1.825 - 1.99
Last Trade Time: 7:36:16 PM EDT
👍️0
Afterhoursearnings3 Afterhoursearnings3 1 year ago
Have 12k shares here now. The data here is extremely valuable.
👍️ 1
mick mick 1 year ago
ME
23andMe Holding Company
2.25
-0.04 (-1.75%)
Volume: 948,040
Day Range: 2.19 - 2.30
Last Trade Time: 7:56:39 PM EDT
👍️0
mick mick 1 year ago
ME
23andMe Holding Company
2.25
-0.04 (-1.75%)
Volume: 948,040
Day Range: 2.19 - 2.30
Last Trade Time: 7:56:39 PM EDT
👍️0
mick mick 1 year ago
ME
23andMe Holding Company
2.51
-0.08 (-3.09%)
Volume: 1,419,788
Day Range: 2.48 - 2.57
Last Trade Time: 7:24:32 PM EST
👍️0
mick mick 1 year ago
ME
23andMe Holding Company
2.59
-0.28 (-9.76%)
Volume: 3,437,659
Day Range: 2.49 - 2.68
Last Trade Time: 6:25:22 PM EST
👍️0
mick mick 1 year ago
ME
23andMe Holding Company
2.59
-0.28 (-9.76%)
Volume: 3,437,659
Day Range: 2.49 - 2.68
Last Trade Time: 6:25:22 PM EST
👍️0
mick mick 1 year ago
ME
23andMe Holding Company
2.68
-0.07 (-2.55%)
Volume: 2,344,468
Day Range: 2.64 - 2.80
Last Trade Time: 7:32:55 PM EST
👍️0
mick mick 1 year ago
ME
23andMe Holding Company
2.64
-0.05 (-1.86%)
Volume: 7,648,803
Day Range: 2.54 - 2.68
Last Trade Time: 7:58:03 PM EST
👍️0
mick mick 2 years ago
ME
23andMe Holding Company
2.8799
-0.0201 (-0.69%)
Volume: 2,373,575
Day Range: 2.78 - 2.92
Bid: 2.38
Ask: 3.37
Last Trade Time: 7:52:48 PM EDT
Total Trades: 12,726
ME Detailed Quote
👍️0
mick mick 2 years ago
ME
Mariner Energy Inc.
26.25
0.00 (0.00%)
Volume: -
ME Detailed Quote
👍️0
mick mick 2 years ago
me too, noted
👍️0
sage4 sage4 2 years ago
Please check below:

( ) I am not a robot.
👍️0
mick mick 2 years ago
ME
Mariner Energy Inc.
26.25
0.00 (0.00%)
Volume: -
ME Detailed Quote
👍️0
mick mick 2 years ago
ME
Mariner Energy Inc.
26.25
0.00 (0.00%)
Volume: -
ME Detailed Quote
👍️0
mick mick 2 years ago
23andMe Holding Comp (ME)
2.69 ? -0.27 (-9.12%)
Volume: 3,365,535 @06/03/22 7:56:26 PM EDT
Bid Ask Day's Range
2.65 2.69 2.67 - 2.9
ME Detailed Quote
👍️0
mick mick 2 years ago
23andMe Holding Comp (ME)
3.01 ? -0.09 (-2.90%)
Volume: 1,841,915 @04/29/22 7:55:36 PM EDT
Bid Ask Day's Range
3.01 3.1 2.97 - 3.21
ME Detailed Quote
👍️0

Your Recent History

NASDAQ
ME
23andMe
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved